A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 138-144

  Mohara, Adun ^a   Velasco, Román Pérez ^a   Praditsitthikorn, Naiyana ^a   Avihingsanon, Yingyos ^b   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Azathioprine; Costs and cost analysis; Cyclophosphamide; Decision support techniques; Economic models; Health care rationing; Immunosuppressive agents; Lupus nephritis; Mycophenolic acid; Thailand

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HUMAN; LIFESPAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE DRUG DOSE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); THAILAND;

AZATHIOPRINE; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DECISION SUPPORT TECHNIQUES; ECONOMIC MODELS; HEALTH CARE RATIONING; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; THAILAND;

COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; THAILAND; TREATMENT OUTCOME;

EID: 84890905500     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket304     Document Type: Article

References (31)

1. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18.
2. Tikly M, Navarra SV. Lupus in the developing world-is it any different? Lupus 2008;22:643-55.
3. Shayakul C, Ong-aj-yooth L, Chirawong P et al. Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients. Am J Kidney Dis 1995;26:300-7.
4. The Nephrology Society of Thailand. Guidelines for treatment lupus nephritis. J Nephrol Soc Thai 1999;5:281-6.
5. Frutos MA, Martín Gómez A, de Ramón E et al. Intravenous cyclophosphamide for lupus nephritis: twenty years reducing the dose. Nefrologia 2007;27:12-22.
6. Ntali S, Bertsias G, Boumpas DT. Cyclophosphamide and lupus nephritis: when, how, for how long? Clin Rev Allergy Immunol 2011;40:181-91.
7. Berden JH. Azathioprine, the Cinderella in the treatment of lupus nephritis. Nephrol Dial Transplant 2009;24:2611-2.
8. Mok C, Wong R, Lai K. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003;62:799-804.
9. Fiehn C. Early diagnosis and treatment in lupus nephritis: how we can influence the risk for terminal renal failure. J Rheumatol 2006;33:1464-6.
10. Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007;10:61-72.
11. Mohara A, Youngkong S, Pérez Velasco R et al. Using health technology assessment for informing coverage decisions in Thailand. J Compar Effect Res 2012;1:137-46.
12. Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai 2008;91(Suppl 2):S53-8.
13. Melo AKG, Avelar AB, Maegawa FKM et al. Analysis of 100 patients with lupus nephritis followed up for 2 years. Rev Bras Reumatol 2009;49:8-19.
14. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10.
15. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
16. Bundhamcharoen K, Aungkulanon S. A study of the burden of disease in the Thai population to inform the health system. Nonthaburi: International Health Policy Program, 2012.
17. Lee YH, Woo JH, Choi SJ et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 2010;19:703-10.
18. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
19. Chan TM, Tse KC, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
20. Sahin GM, Sahin S, Kiziltas S et al. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Ren Fail 2008;30:865-9.
21. Yee CS, Gordon C, Dostal C et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004;63:525-9.
22. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69:2083-9.
23. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
24. Mok CC, Ho CT, Siu YP et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
25. Drug and Medical Supply Information Center. Price of drugs and medical devices. Nonthaburi: Ministry of Public Health, 2008.
26. Health Intervention and Technology Assessment Program. Standard cost lists for health technology assessment. Nonthaburi: HITAP, 2011.
27. Central Office for Healthcare Information. Ministry of Public Health. Hospital database, 2008-2010. Bangkok: Central Office for Healthcare Information, 2012.
28. Bureau of Trade and Economic Indices, Ministry of Commerce. Report for consumer price index (medical and personal care) of Thailandbase year 2007, http://www.price.moc.go.th/en/content1.aspx?cid=1 (29 August 2013, date last accessed).
29. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period. a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82:299-308.
30. Wilson EC, Jayne DR, Dellow E et al. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis. Rheumatology 2007;46:1096-101.
31. Apple G. New and future therapies for lupus nephritis. Cleve Clin J Med 2012;79:134-40.